---
reference_id: "PMID:36736290"
title: Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.
authors:
- Sebert M
- Gachet S
- Leblanc T
- Rousseau A
- Bluteau O
- Kim R
- Ben Abdelali R
- Sicre de Fontbrune F
- Maillard L
- Fedronie C
- Murigneux V
- Bellenger L
- Naouar N
- Quentin S
- Hernandez L
- Vasquez N
- Da Costa M
- Prata PH
- Larcher L
- de Tersant M
- Duchmann M
- Raimbault A
- Trimoreau F
- Fenneteau O
- Cuccuini W
- Gachard N
- Auger N
- Tueur G
- Blanluet M
- Gazin C
- Souyri M
- Langa Vives F
- Mendez-Bermudez A
- Lapillonne H
- Lengline E
- Raffoux E
- Fenaux P
- Adès L
- Forcade E
- Jubert C
- Domenech C
- Strullu M
- Bruno B
- Buchbinder N
- Thomas C
- Petit A
- Leverger G
- Michel G
- Cavazzana M
- Gluckman E
- Bertrand Y
- Boissel N
- Baruchel A
- Dalle JH
- Clappier E
- Gilson E
- Deriano L
- Chevret S
- Sigaux F
- Socié G
- Stoppa-Lyonnet D
- de Thé H
- Antoniewski C
- Bluteau D
- Peffault de Latour R
- Soulier J
journal: Cell Stem Cell
year: '2023'
doi: 10.1016/j.stem.2023.01.006
content_type: abstract_only
---

# Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.
**Authors:** Sebert M, Gachet S, Leblanc T, Rousseau A, Bluteau O, Kim R, Ben Abdelali R, Sicre de Fontbrune F, Maillard L, Fedronie C, Murigneux V, Bellenger L, Naouar N, Quentin S, Hernandez L, Vasquez N, Da Costa M, Prata PH, Larcher L, de Tersant M, Duchmann M, Raimbault A, Trimoreau F, Fenneteau O, Cuccuini W, Gachard N, Auger N, Tueur G, Blanluet M, Gazin C, Souyri M, Langa Vives F, Mendez-Bermudez A, Lapillonne H, Lengline E, Raffoux E, Fenaux P, Adès L, Forcade E, Jubert C, Domenech C, Strullu M, Bruno B, Buchbinder N, Thomas C, Petit A, Leverger G, Michel G, Cavazzana M, Gluckman E, Bertrand Y, Boissel N, Baruchel A, Dalle JH, Clappier E, Gilson E, Deriano L, Chevret S, Sigaux F, Socié G, Stoppa-Lyonnet D, de Thé H, Antoniewski C, Bluteau D, Peffault de Latour R, Soulier J
**Journal:** Cell Stem Cell (2023)
**DOI:** [10.1016/j.stem.2023.01.006](https://doi.org/10.1016/j.stem.2023.01.006)

## Content

1. Cell Stem Cell. 2023 Feb 2;30(2):153-170.e9. doi: 10.1016/j.stem.2023.01.006.

Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical 
route toward leukemia in Fanconi anemia.

Sebert M(1), Gachet S(2), Leblanc T(3), Rousseau A(4), Bluteau O(5), Kim R(2), 
Ben Abdelali R(2), Sicre de Fontbrune F(6), Maillard L(5), Fedronie C(5), 
Murigneux V(7), Bellenger L(8), Naouar N(8), Quentin S(2), Hernandez L(5), 
Vasquez N(9), Da Costa M(9), Prata PH(5), Larcher L(9), de Tersant M(5), 
Duchmann M(5), Raimbault A(2), Trimoreau F(10), Fenneteau O(11), Cuccuini W(2), 
Gachard N(10), Auger N(12), Tueur G(2), Blanluet M(13), Gazin C(14), Souyri 
M(15), Langa Vives F(16), Mendez-Bermudez A(17), Lapillonne H(18), Lengline 
E(19), Raffoux E(19), Fenaux P(1), Adès L(1), Forcade E(20), Jubert C(20), 
Domenech C(21), Strullu M(22), Bruno B(23), Buchbinder N(24), Thomas C(25), 
Petit A(26), Leverger G(26), Michel G(27), Cavazzana M(28), Gluckman E(29), 
Bertrand Y(21), Boissel N(30), Baruchel A(31), Dalle JH(31), Clappier E(2), 
Gilson E(17), Deriano L(7), Chevret S(32), Sigaux F(2), Socié G(33), 
Stoppa-Lyonnet D(13), de Thé H(34), Antoniewski C(8), Bluteau D(35), Peffault de 
Latour R(36), Soulier J(37).

Author information:
(1)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 Paris, 
France; Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France; INSERM U944/CNRS UMR7212, 
Paris, France.
(2)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 Paris, 
France; INSERM U944/CNRS UMR7212, Paris, France; Saint-Louis Hospital, 
Hematology Laboratory, APHP, Paris, France.
(3)Robert Debré Hospital, Department of Pediatric Hematology, Paris, France; EA 
3518, IRSL, Paris, France; Centre de Référence Maladies Rares "Aplasie 
Médullaire", Saint-Louis and Robert Debré Hospitals, Paris, France.
(4)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 Paris, 
France.
(5)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 Paris, 
France; INSERM U944/CNRS UMR7212, Paris, France.
(6)Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France; EA 3518, IRSL, Paris, France; 
Centre de Référence Maladies Rares "Aplasie Médullaire", Saint-Louis and Robert 
Debré Hospitals, Paris, France.
(7)Genome Integrity, Immunity and Cancer Unit, INSERM U1223, Equipe Labellisée 
Ligue Contre Le Cancer, Institut Pasteur, Paris, France.
(8)Sorbonne Université, CNRS FR3631, INSERM US037, Institut de Biologie Paris 
Seine (IBPS), ARTbio Bioinformatics Analysis Facility, Institut Français de 
Bioinformatique (IFB), Paris, France.
(9)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 Paris, 
France; INSERM U944/CNRS UMR7212, Paris, France; Saint-Louis Hospital, 
Hematology Laboratory, APHP, Paris, France; Centre de Référence Maladies Rares 
"Aplasie Médullaire", Saint-Louis and Robert Debré Hospitals, Paris, France.
(10)Saint-Louis Hospital, Hematology Laboratory, APHP, Paris, France; Hematology 
Laboratory, CHU Limoges, Limoges, France.
(11)Hematology Laboratory, Robert Debré Hospital, Paris, France.
(12)Département de Biologie et Pathologie Médicales, Institut de Cancérologie 
Gustave Roussy, Villejuif, France.
(13)Department of Genetics, Institut Curie, Université de Paris, INSERM U830, 
Paris, France.
(14)INSERM U944/CNRS UMR7212, Paris, France; Centre National de Recherche en 
Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Evry, 
France.
(15)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; INSERM UMR S1131, Hôpital Saint Louis, Paris, France.
(16)Mouse Genetics Engineering Center, Pasteur Institute, Paris, France.
(17)Université Côte d'Azur, CNRS, Inserm, Institute for Research on Cancer and 
Aging, Nice (IRCAN), France; Department of Medical Genetics, CHU, Nice, France.
(18)Hematology Laboratory, Trousseau Hospital and HUEP, Paris, France.
(19)Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France.
(20)CHU Bordeaux, Service d'Hématologie et Thérapie Cellulaire et Unité 
d'Hématologie Oncologie Pédiatrique, 33000 Bordeaux, France.
(21)Institut of Hematology and Pediatric Oncology (IHOP), Hospices Civils de 
Lyon, France; Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS 
5286, Centre Léon Bérard, Université Lyon 1, Lyon, France.
(22)Robert Debré Hospital, Department of Pediatric Hematology, Paris, France; EA 
3518, IRSL, Paris, France.
(23)CHU de Lille, Pediatrics Hematology, Lille, France.
(24)Centre Pédiatrique de Transplantation de Cellules Souches Hématopoïétiques, 
CHU de Rouen, Rouen, France.
(25)Service d'Oncologie-Hématologie et Immunologie Pédiatrique, CHU de Nantes, 
Nantes, France.
(26)Pediatric Hematology-Oncology, Trousseau Hospital and HUEP, Paris, France.
(27)Timone Enfants Hospital, Department of Pediatric Hematology and Oncology, 
Aix-Marseille University, EA 3279, Marseille, France.
(28)Biotherapy Department, Necker Children's Hospital, APHP Centre, Biotherapy 
Clinical Investigation Center, Inserm U1416, University of Paris, Imagine 
Institute, Paris, France.
(29)Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France; Eurocord, Department of 
Hematology, Saint-Louis Hospital, Paris, France.
(30)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France; EA 3518, IRSL, Paris, France.
(31)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; Robert Debré Hospital, Department of Pediatric Hematology, Paris, 
France; EA 3518, IRSL, Paris, France; Centre de Référence Maladies Rares 
"Aplasie Médullaire", Saint-Louis and Robert Debré Hospitals, Paris, France.
(32)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; Division of Biostatistics, Saint-Louis Hospital, APHP, Paris, 
France.
(33)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France; INSERM UMR-976, Saint-Louis 
Hospital, Paris, France; Centre de Référence Maladies Rares "Aplasie 
Médullaire", Saint-Louis and Robert Debré Hospitals, Paris, France.
(34)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; INSERM U944/CNRS UMR7212, Paris, France; Saint-Louis Hospital, 
Hematology Laboratory, APHP, Paris, France; Collège de France, Paris, France.
(35)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; INSERM U944/CNRS UMR7212, Paris, France; EPHE, PSL University, 
Paris, France. Electronic address: dominique.bluteau@ephe.psl.eu.
(36)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; Clinical Hematology Departments, Saint-Louis Hospital, Assistance 
Publique-Hôpitaux de Paris (APHP), Paris, France; EA 3518, IRSL, Paris, France; 
Centre de Référence Maladies Rares "Aplasie Médullaire", Saint-Louis and Robert 
Debré Hospitals, Paris, France.
(37)Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 
Paris, France; INSERM U944/CNRS UMR7212, Paris, France; Saint-Louis Hospital, 
Hematology Laboratory, APHP, Paris, France; Centre de Référence Maladies Rares 
"Aplasie Médullaire", Saint-Louis and Robert Debré Hospitals, Paris, France. 
Electronic address: jean.soulier@aphp.fr.

Fanconi anemia (FA) patients experience chromosome instability, yielding 
hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to 
poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, 
we performed clinical, genomic, and functional studies in 62 patients with 
clonal evolution. We found a unique pattern of somatic structural variants and 
mutations that shares features of BRCA-related cancers, the FA-hallmark being 
unbalanced, microhomology-mediated translocations driving copy-number 
alterations. Half the patients developed chromosome 1q gain, driving clonal 
hematopoiesis through MDM4 trisomy downmodulating p53 signaling later followed 
by secondary acute myeloid lukemia genomic alterations. Functionally, MDM4 
triplication conferred greater fitness to murine and human primary FA HSPCs, 
rescued inflammation-mediated bone marrow failure, and drove clonal dominance in 
FA mouse models, while targeting MDM4 impaired leukemia cells in vitro and 
in vivo. Our results identify a linear route toward secondary leukemogenesis 
whereby early MDM4-driven downregulation of basal p53 activation plays a pivotal 
role, opening monitoring and therapeutic prospects.

Copyright © 2023. Published by Elsevier Inc.

DOI: 10.1016/j.stem.2023.01.006
PMID: 36736290 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests J.S. is scientific 
advisor for STRM.BIO, Inc (Boston, USA).